Pharmacy Update
Disclaimer: We are getting frequent COVID-related questions about drug concerns and potential interactions. This information is as of June 11, 2020. We will do our best to keep you up to date with this ever evolving situation. This is the most update information at the time of publication.
Note: There are no Food and Drug Administration
(FDA) approved therapies for treatment or prevention of COVID-19. If at all possible, it is best to have patients enrolled in a clinical trial.
In this issue:
HYDROXYCHLOROQUINE FOR POST-EXPOSURE PROPHYLAXIS OF COVID-19 -
Hydroxychloroquine is being studied for both treatment and prevention of COVID-19 infection. Hydroxychloroquine has in vitro activity against SARS-CoV-2.
REMDESIVIR WITH BARICITINIB -
Currently, there is no evidence to support the use of remdesivir or baricitinib for COVID-19 treatment outside of a clinical trial setting.
ALERT: ARTICLE RETRACTIONS: HYDROXYCHLOROQUINE IN COVID-19
-
Retractions were issued June 5, 2020 on two articles involving data from Surgisphere Corporation, an international registry of the Surgical Outcomes Collaborative.
